✦ LIBER ✦

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

✍ Scribed by Alfonso Quintás-Cardama; Jorge E. Cortes; Susan O'Brien; Farhad Ravandi; Gautam Borthakur; David Liu; Eric Bleickardt; Tai-Tsang Chen; Hagop M. Kantarjian

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 182 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24325

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dynamics and management of cytopenias as

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure

✍ Alfonso Quintás-Cardama; Fabio Pires De Souza Santos; Hagop Kantarjian; Susan O' 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB 👁 2 views

## Abstract ## BACKGROUND: The incidence, dynamics, and management of cytopenias were investigated in patients with chronic myeloid leukemia in chronic phase (CP CML) who received dasatinib therapy after imatinib failure. ## METHODS: Data were analyzed from 130 patients with CP CML who were trea

Efficacy and safety of imatinib in patie

Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α

✍ Susan Branford; Timothy Hughes; Alvin Milner; Rachel Koelmeyer; Anthony Schwarer 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 1 views

## Abstract ## BACKGROUND. Interferon‐alpha (IFN‐α) confers a survival advantage for the minority of patients with chronic myeloid leukemia (CML) who achieve a complete cytogenetic response. The question of whether IFN‐α‐responsive patients can experience further improvements with imatinib has not

Sudden blast crisis in patients with Phi

Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy

✍ Giuliana Alimena; Massimo Breccia; Roberto Latagliata; Ida Carmosino; Eleonora R 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

Pilot study of lonafarnib, a farnesyl tr

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

✍ Gautam Borthakur; Hagop Kantarjian; George Daley; Moshe Talpaz; Susan O'Brien; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

Dasatinib in imatinib-resistant or imati

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study : Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

✍ Giuseppe Saglio; Andreas Hochhaus; Yeow Tee Goh; Tamas Masszi; Ricardo Pasquini; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 373 KB

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH